Bialy L P, Kuckelkorn U, Henklein P, Fayet J, Wilczyński G M, Kamiński A, Mlynarczuk-Bialy I
Department of Histology and Embryology, Center for Biostructure Research, Medical University of Warsaw, Warsaw, Poland.
Institut für Biochemie, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Histol Histopathol. 2019 Apr;34(4):359-372. doi: 10.14670/HH-18-042. Epub 2018 Sep 18.
Extralysosomal proteolysis is a multistep process involving the Ubiquitin- Proteasome System (UPS) and supplementary peptidases. Tripeptidyl peptidase II (TPPII) is the most extensively characterized enzyme, supplementing and sometimes substituting for proteasomal functions. In response to proteasome inhibition, polyubiquitinated proteins acting as proteasome substrates aggregate with proteasomes and form aggresomes. Several proteasome inhibitors are used as anti-cancer drugs. Thus, in our study, we used a novel fluorescent-tagged proteasome inhibitor BSc2118 to induce aggresome formation in C26 murine colon adenocarcinoma cells. It allowed us to obtain effective, inhibitor-based, proteasome staining in vivo. This method has been validated by standard post-fixed indirect immunostaining and also allowed co-immunodetection of TPPII and polyubiquitinated proteins under laser scanning confocal microscopy. We found that in the absence of the inhibitor, TPPII is diffusely dispersed within the cytoplasm of C26 cells. The proteasome and ubiquitin-rich perinuclear region failed to display enhanced TPPII staining. However, when proteasome function was impaired by the inhibitor, TPPII associated more closely with both the proteasome and polyubiquitinated proteins via TPPII recruitment to the perinuclear region and subsequently into emerging aggresomal structures. Furthermore, we have demonstrated the dynamic recruitment of TPPII into the developing aggresome: TPPII in the early aggresome was dispersed within the central part but subsequently aggregated on the surface of this structure. In the mature aggresome of C26 cells TPPII formed a spherical mantle, which surrounded the round core containing proteasomes and polyubiquitinated proteins. Our morphological data indicate that TPPII displays spatial localization with proteasomes especially upon proteasome inhibition in aggresomes of C26 cells.
溶酶体外蛋白水解是一个多步骤过程,涉及泛素-蛋白酶体系统(UPS)和补充性肽酶。三肽基肽酶II(TPPII)是特征最为广泛的酶,它补充并有时替代蛋白酶体的功能。响应蛋白酶体抑制,作为蛋白酶体底物的多聚泛素化蛋白与蛋白酶体聚集并形成聚集体。几种蛋白酶体抑制剂被用作抗癌药物。因此,在我们的研究中,我们使用了一种新型荧光标记的蛋白酶体抑制剂BSc2118,以诱导C26小鼠结肠腺癌细胞中聚集体的形成。这使我们能够在体内获得基于抑制剂的有效蛋白酶体染色。该方法已通过标准的后固定间接免疫染色得到验证,并且还能在激光扫描共聚焦显微镜下对TPPII和多聚泛素化蛋白进行共免疫检测。我们发现,在没有抑制剂的情况下,TPPII分散在C26细胞的细胞质中。富含蛋白酶体和泛素的核周区域未显示增强的TPPII染色。然而,当蛋白酶体功能被抑制剂损害时,TPPII通过被招募到核周区域并随后进入新出现的聚集体结构,而与蛋白酶体和多聚泛素化蛋白更紧密地结合。此外,我们证明了TPPII动态招募到正在形成的聚集体中:早期聚集体中的TPPII分散在中心部分,但随后聚集在该结构的表面。在C26细胞的成熟聚集体中,TPPII形成了一个球形外壳,围绕着包含蛋白酶体和多聚泛素化蛋白的圆形核心。我们的形态学数据表明,TPPII与蛋白酶体呈现空间定位关系,尤其是在C26细胞聚集体中蛋白酶体受到抑制时。